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OBJECTIVE — Measures of baroreflex sensitivity, heart rate variability (HRV), and the clas-
sical Ewing test parameters are currently used for the diagnosis of diabetic autonomic neurop-
athy and for mortality risk stratification after myocardial infarction. However, the strengths of the
associations of these measures of autonomic function with risk of mortality have never been
compared in one study population. Furthermore, no evidence is available on the possible effect
of glucose tolerance on these associations.
RESEARCHDESIGNANDMETHODS — The study population (n 605) consisted of
a glucose tolerance–stratified sample from a general population (50–75 years of age). Cardiac
cycle duration and continuous finger arterial pressure were measured under two conditions: at
rest and on metronome breathing. From these readings, seven parameters of autonomic function
were assessed (one Ewing, five HRV, and one baroreflex sensitivity).
RESULTS — During 9 years of follow-up, 101 individuals died, 43 from cardiovascular
causes. Subjects with diabetes and low levels of the autonomic function parameters, indicating
impaired autonomic function, had an approximately doubled risk of mortality. This association
was consistent, though not statistically significant, for all parameters. The elevated risk was not
observed in subjects without diabetes, hypertension, or prevalent cardiovascular disease.
CONCLUSIONS — Impaired autonomic function is associated with all-cause and cardio-
vascular mortality. Moreover, the results of the present study suggest that cardiac autonomic
dysfunction in patients already at risk (diabetes, hypertension, or history of cardiovascular
disease) may be especially hazardous.
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D ysfunction of the autonomic ner-vous system is associated with in-creased risk of mortality in patients
with diabetes (1,2), survivors of myocar-
dial infarction (3,4), and unselected mid-
dle-aged and elderly subjects (5,6). This
has been explained by the fact that auto-
nomic imbalance predisposes individuals
to cardiac arrhythmias (7). The associa-
tion of autonomic imbalance with inci-
dent cardiovascular disease and all-cause
mortality in the general population has
been attributed to subclinical coronary
artery disease or otherwise poor health
(5,6). Another possibility, addressed only
marginally in these studies, might be glu-
cose intolerance. Subjects with diabetes
are known be at high risk of developing
autonomic dysfunction, and autonomic
dysfunction is already present in patients
with newly diagnosed diabetes (8). Gly-
cemic parameters are associated with
death from all causes in patients with di-
abetes, impaired glucose tolerance (IGT)
(9), and even normal glucose tolerance
(10,11). However, impaired autonomic
function and mortality so far have not
been studied in relation to glucose intol-
erance.
Numerous tests exist to assess cardio-
vascular autonomic function, based on
measurement of beat-to-beat changes in
heart rate and/or blood pressure. These
tests may be classified into three groups:
1) classical Ewing tests (12), including the
deep breathing and lying-to-standing
test; 2) spectral analysis of spontaneous
heart rate variability (HRV) (13,14); and
3) baroreflex sensitivity (BRS), the heart
rate response following a change in blood
pressure. The different types of auto-
nomic function measures so far have not
been compared in one single study pop-
ulation.
Therefore, we studied the association
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of several autonomic function measures
with mortality in 50- to 75-year-old men
and women, with special reference to the
possible confounding or effect-modifying
role of glucose intolerance and cardiovas-
cular disease.
RESEARCH DESIGN AND
METHODS
Study population
The present study is part of the Hoorn
Study, a prospective study of glucose tol-
erance in a general population of Cauca-
sian subjects (50–75 years of age) (11).
The baseline examination was conducted
in 1989–1992, as previously described in
detail (15). Briefly, a random sample was
drawn from the municipal population of
Hoorn, the Netherlands. All 2,484 partic-
ipants (71%), except those who were taking
glucose-lowering medication, underwent
75-g oral glucose tolerance testing. A
sample of 708 subjects, stratified by 2-h
glucose values, age, and gender, was in-
vited to undergo extensive examinations
of diabetes-related complications, and
631 subjects (89%) participated. For the
present analyses, we excluded subjects
who had pacemakers (n  2), who were
taking antiarrhythmic medication (n 
17), or who had self-reported neurologic
disease (n  8), resulting in a study pop-
ulation of 605 subjects.
Baseline examination
Fasting and 2-h plasma glucose levels
were determined with a glucose dehydro-
genase method (Merck, Darmstadt, Ger-
many). Subjects were classified into
glucose tolerance groups, based on the
mean values of two oral glucose tolerance
tests (16). A total of 282 individuals had
normal glucose tolerance (NGT), 164 had
IGT, 85 had newly diagnosed diabetes,
and 74 had known type 2 diabetes, as
defined by the use of a diet or glucose-
lowering medication. HbA1c was deter-
mined by ion-exchange high-performance
l iquid chromatography (Bio-Rad,
Veenendaal, the Netherlands).
Blood pressure was measured in du-
plicate on two separate occasions on the
right arm of seated subjects after at least 5
min of rest, by means of a random-zero
sphygmomanometer (Hawksley-Gelman,
Lancing, Sussex, U.K.). The averages of
the four blood pressure readings were cal-
culated. Hypertension was defined as a
systolic blood pressure 160 mmHg, a
diastolic blood pressure 95 mmHg,
and/or the use of antihypertensives (17).
These cutoff points were used because of
the definition of hypertension at the time
of the data collection. Use of antihyper-
tensives was defined as current treatment
with alpha blockers, beta blockers, cal-
cium antagonists, angiotensin-converting
enzyme inhibitors, diuretics, and/or a rest
group including centrally acting antihy-
pertensives.
Cardiovascular disease was defined as
coronary artery, cerebrovascular, and/or
peripheral arterial disease. Coronary ar-
tery disease was defined as self-reported
history of myocardial infarction, coronary
artery bypass grafting, or Minnesota
codes 1-1 or 1-2 on electrocardiography.
Peripheral arterial disease was defined as
self-reported peripheral arterial recon-
struction, nontraumatic limb amputa-
tion, and/or an ankle brachial pressure
index 0.50 (18). Cerebrovascular dis-
ease was defined as self-reported history
of stroke or carotid stenosis 80%
(19,20).
For assessment of cardiac autonomic
function, participants were asked to re-
frain from smoking and drinking coffee
for 2 h before the tests. Tests took place
between 8:30 A.M. and 4:00 P.M., at least
1 h after participants ate a light meal, in a
quiet ambience with room temperature of
19–22°C. Cardiac cycle duration (R-R in-
terval) and continuous finger arterial
pressure were continuously recorded on a
PC-based data-acquisition system, in su-
pine position 1) during spontaneous
breathing for 3 min and 2) during metro-
nome breathing at six breaths/min for 1
min. When off-line spectral analysis
showed that breathing was not performed
at the appropriate frequency, the record
was discarded. The test session started
with a resting period of at least 10 min.
R-R intervals were obtained by electrocar-
diography using a QRS detector with an
accuracy of 1 ms. Blood pressure was re-
corded using the Finapres method (finger
arterial blood pressure, model BP2000;
Ohmeda, Englewood, CO) (20). Systolic
blood pressure values were obtained from
the sampled blood pressure signal by
means of an automatic procedure, which
was verified by visual inspection.
Seven measures of cardiovascular au-
tonomic function were computed, as pre-
viously described in detail (14,18,21,22)
(Table 1). Individual data were missing
(57 for spectral measures, 51 for Ewing
tests, 87 for BRS) because the test sched-
ule was not completed, because the test
was not performed correctly, or because
the quality of the data were insufficient for
processing.
Follow-up examination
Information on vital status was obtained
from the population register of the city of
Hoorn. Causes of death were obtained
from the medical records at the general
practices, the local hospital, and the local
nursing home and coded according to the
International Classification of Diseases, Inju-
ries and Causes of Death, 9th Revision
(ICD-9) (23). Cardiovascular disease
mortality, including sudden death, was
defined by the ICD-9 codes 390-459 and
798.
The study protocol was approved by
the Ethics Committee of the University
Hospital of the Vrije Universiteit. All
study participants gave informed consent.
Statistical analysis
All analyses were performed using SPSS
statistical software (SPSS, Chicago, IL).
For survival analyses, the lowest 25th per-
centile values of the autonomic function
measures in the NGT group were consid-
ered the cutoff to define autonomic dys-
function. There are no generally accepted
cutoff points to define impaired auto-
nomic function, and furthermore, there
are indications that the association with
mortality risk may not be continuous. The
lower quartile was selected to have sub-
stantial numbers in each group for the sta-
tistical analysis. Hazard ratios (relative
risk) and 95% CIs for determinants of car-
diovascular and all-cause mortality were
determined by Cox’s proportional haz-
ards analysis. All analyses were adjusted
for age, gender, and glucose tolerance be-
cause of the stratification procedure. We
primarily adjusted for other risk factors
that were statistically significantly associ-
ated with mortality and secondarily for all
other risk factors. As possible confound-
ers, we considered BMI, HbA1c, fasting
insulin, total cholesterol, HDL choles-
terol, current smoking (yes/no), and alco-
hol consumption (yes/no). To test for
possible effect modification, the risk fac-
tor of interest, the autonomic function
measure under consideration, and the
product term were included in the model.
A significant product term was inter-
preted as effect modification by that risk
factor. Whenever effect modification was
Autonomic function and mortality
1794 DIABETES CARE, VOLUME 24, NUMBER 10, OCTOBER 2001
likely, a stratified analysis was performed.
For all analyses, two-sided probability
values 0.05 were considered statisti-
cally significant.
RESULTS — Follow-up continued un-
til January 1999. Median follow-up was
7.9 years (range 0.5–9.2). During the fol-
low-up period, 101 of the 605 persons
died. Information on cause of death could
not be obtained for 14 of the subjects who
had died, because the individuals had
moved and medical records could not be
retrieved. The baseline characteristics for
survivors (n 504) and nonsurvivors are
shown in Table 2 . Subjects who died had
significantly lower scores on all parame-
ters of autonomic function, except for the
HRV power ratio, than those who sur-
vived (Table 2).
Cutoff points for impaired autonomic
function, taken from the lowest 25th per-
centile in the NGT group, were 878 ms for
the mean of all normal-to-normal (NN)
(sinus rhythm) R-R intervals, 25.7 ms for
the standard deviation of all NN (sinus
rhythm) R-R intervals (SDNN), 125 ms2
for low-frequency (LF) power in the R-R–
interval spectrum between 0.04 and 0.12
Hz, 93 ms2 for high-frequency (HF)
power in the R-R interval spectrum be-
tween 0.12 and 0.40 Hz, 0.41 for LF/(LF
 HF), 107 ms for expiration-inspiration
(EI) difference in R-R intervals during
breathing at six breaths/min, and 6.1 ms/
mmHg for BRS.
The survival analyses, shown in Table
3, yielded systematically different results
for subjects with and without diabetes. In
diabetic subjects, but not in nondiabetic
subjects, impaired autonomic function
was consistently associated with an ap-
proximately doubled risk of mortality but
was not statistically significant for all pa-
rameters. Of these seven parameters of
autonomic function, EI difference was
significantly associated with all-cause
mortality, after adjustment for age, gen-
der, and glucose tolerance, and an addi-
tional four parameters showed a tendency
(P  0.10): mean NN, LF power, HF
power, and BRS. A survival curve of cate-
gories of the EI difference is shown in Fig.
1. For six of the seven measures of auto-
nomic function, the relative risks were
slightly higher in diabetic subjects than in
nondiabetic subjects; for SDNN, the
product term was significant. The associ-
ations with cardiovascular disease mortal-
ity were similar.
Further stratified analyses showed an
elevated risk of mortality associated with
low autonomic function in subjects with
hypertension, subjects taking antihyper-
tensive medication, or subjects with a his-
tory of cardiovascular disease (data not
shown). Therefore, a stratified analysis
was performed for subjects at low or high
risk, with high risk defined as the pres-
ence of diabetes and/or hypertension
and/or a history of cardiovascular disease.
In subjects at low risk, impaired auto-
nomic function did not seem to be asso-
ciated with all-cause or cardiovascular
mortality. In the high-risk group, how-
ever, autonomic dysfunction showed a
consistent association with mortality but
was not statistically significant for all pa-
rameters (Table 3). For the EI difference,
the product term, indicative of effect-
modification by baseline risk, was signif-
icant.
Potentially confounding variables
that were statistically significantly associ-
ated with all-cause mortality were BMI,
smoking, and fasting insulin (data not
shown). Including these potentially con-
founding variables into the models did
not materially change the estimated rela-
tive risks for impaired autonomic func-
tion.
CONCLUSIONS — This study shows
that autonomic function parameters are
associated with risk of all-cause and car-
diovascular death, even after adjustment
for age, gender, glucose tolerance, and use
of antihypertensive medication. The
strength of the relation between survival
and autonomic function was generally
stronger in subjects with diabetes, hyper-
Table 1—Overview of the seven measures of cardiovascular autonomic function
Measure Unit Definition
During spontaneous breathing for 3 min in the supine position:
Mean NN ms The mean of all normal-to-normal (sinus rhythm) R-R
intervals*
SDNN ms The standard deviation of all normal-to-normal (sinus rhythm)
R-R intervals*
LF power ms2 Low-frequency power, in absolute units: energy in the power
spectrum between 0.04 and 0.12 Hz*
HF power ms2 High frequency power, in absolute units: energy in the power
spectrum between 0.12 and 0.40 Hz*
LF/(LF  HF) The ratio of low-frequency power to the sum of the low- and
high-frequency power*
During six deep breaths for 1 min in the supine position:
EI difference ms The mean expiration-inspiration difference in R-R intervals
over the six consecutive breaths†
BRS ms/mmHg A measure of baroreflex sensitivity, computed as gain, i.e., ratio
of the energy, in the cross-spectrum of systolic blood
pressure and R-R intervals and the energy in the power
spectrum of the R-R interval, all between 0.05 and 0.15 Hz
and with a squared coherence (2) of 0.5 or higher‡
*See reference no. 14; †see reference no. 12; ‡see reference no. 21.
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tension, and/or a history of cardiovascular
disease.
Methodological issues
Relatively short recordings of heart rate
variability (15 s to 15 min) have been
shown to be predictive for both cardio-
vascular and all-cause mortality in post-
myocardial infarction patients and also in
the general population (3,5). Autonomic
function assessment is used mainly in two
clinical fields: in cardiology for risk-
stratification after myocardial infarction
and in internal medicine to assess (diabet-
ic) autonomic neuropathy. Cardiologists
tend to use HRV measures (SDNN, LF
power, and HF power) as obtained from
24-h Holter monitor recordings (14),
whereas internists tend to use controlled
breathing and the lying-to-standing ma-
neuver (12,24), both known as Ewing
tests, although HRV analysis has been in-
troduced as well. Recently, the BRS has
gained more interest (4,25). The current
study is the first to address all these mea-
sures of autonomic function: Ewing test,
HRV, and BRS. In general, the measures
obtained from the deep-breathing test (EI
difference and BRS) showed the highest
relative risks, especially in individuals
with hypertension or diabetes. However,
the measures obtained during spontane-
ous breathing also showed a clear associ-
ation with mortality. Use of certain
medication, such as beta blockers and
sympaticomimetics, may be confounding
because they affect autonomic nervous
system function (14,18). Therefore, addi-
tional stratified analyses were performed,
and indeed, hypertension and use of an-
tihypertensives were effect modifiers.
This finding has not been reported before
and has not been taken into account in
previous studies (3–5). In the present
study, a large proportion of the diabetic
subjects were taking antihypertensive
medication; the initial tendency of effect
modification by diabetes was partly at-
tributable to the differences in use of an-
tihypertensives in the diabetic subjects
(40 vs. 23% in nondiabetic subjects).
In the present study, the lowest quar-
tiles of the distribution of autonomic
function parameters were taken as indica-
tions for impaired autonomic function. In
this population-based study, few subjects
had levels lower than previously reported
cutoff points. However, when we did ap-
ply these cutoff points to our data, the
estimated relative risks were not consis-
tently higher, and the results with respect
to the observed interaction with high-risk
status were similar.
Previous studies
Studies on the relation between auto-
nomic function and survival in diabetes
are scarce (2,26). This is the first study to
address the influence of diabetes on the
association between autonomic function
parameters and mortality in a large co-
hort, stratified by glucose intolerance.
The Framingham Heart Study (6), the
Zutphen study (5), and the Autonomic
Tone and Reflexes After Myocardial In-
farction (ATRAMI) study (4) have shown
that impaired autonomic function is pre-
dictive for (cardiovascular) death, both in
the general population and after myocar-
dial infarction. In the Zutphen Study (5),
these possible effect modifiers (4,5) were
Table 2—Baseline characteristics and measures of autonomic function
Survivors (n  504)
Nonsurvivors (n  101)
Deaths from all causes
(n  101)
Cardiovascular deaths
(n  43)
Age (years) 63.5 (7.0) 68.5 (6.3) 68.7 (6.6)
Sex (% male) 47.8 49.5 53.5
Type 2 diabetes (%) 22.8 43.6 46.5
Impaired glucose tolerance (%) 27.6 24.8 23.3
BMI (kg/m2) 27.0 (3.9) 28.5 (4.4) 28.7 (4.7)
Current smokers (%) 25.6 30.7 30.2
Alcohol consumption (%) 64.3 60.4 58.1
Prevalence of cardiovascular disease (%) 30.6 57.4 67.4
Hypertension (%) 34.5 57.4 65.1
Antihypertensive drug treatment (%) 24.2 42.6 48.8
Total cholesterol (mmol/l) 6.65  1.18 6.71  1.16 6.77  1.21
HDL cholesterol (mmol/l) 1.29  0.36 1.23  0.35 1.19  0.35
HbA1c (%) 5.8  1.2 6.4  1.6 6.5  1.3
Fasting insulin (pmol/l)* 82 (46–151) 93 (44–197) 100 (45–191)
Autonomic function measures
Mean NN (ms) 953  150 902  144† 903  127†
SDNN (ms)* 33.2 (18.8–56.5) 27.7 (13.7–55.8)† 26.0 (9.4–55.4)†
LF power (ms2)* 233 (61–945) 153 (18–640)† 134 (15–519)†
HF power (ms2)* 183 (37–835) 123 (16–747)† 137 (15–1022)†
LF/(LF  HF) 0.58  0.19 0.53  0.22 0.49  0.23
EI difference (ms)* 158 (74–336) 126 (45–318)† 113 (46–329)†
BRS (ms/mmHg)* 7.8 (3.4–14.4) 6.4 (2.2–13.3)† 6.3 (2.2–14.2)†
Data are means  SD, %, and 95% CI unless otherwise indicated. *Given are the median (10th to 90th percentiles); †nonsurvivors differed from the survivors,
Student’s t test P 0.05 (only autonomic function measures were tested; Student’s t tests were performed using the ln-transformed values). See Table 1 for definition
of autonomic function measures.
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not taken into account, whereas in the
Framingham Heart Study, data have been
adjusted for diabetes and use of diuretics.
However, as we observed in our study,
diabetes and hypertension may be effect
modifiers, and in that case, a stratified
analysis is indicated to present the results.
In the ATRAMI study, subjects with type
1 diabetes were excluded, but hyperten-
sion or use of antihypertensives was not
accounted for. These differences of ac-
counting for diabetes and use of antihy-
pertensives, together with the different
ways of assessing autonomic function, the
different cutoff points used, and the dif-
ferent populations, limit detailed compar-
ison with previous results. However, the
association of autonomic dysfunction
with mortality risk is consistent. Our
study confirms this for a Ewing test mea-
sure, HRV measures, and BRS. We showed
that these associations were especially
strong in a high-risk population, defined
by the presence of diabetes, hypertension,
and/or a history of cardiovascular disease.
Possible mechanisms
The increased risk of mortality in myocar-
dial patients with impaired autonomic
function can be attributed to the elevated
risk of life-threatening arrhythmia (3,14).
In the general population, impaired auto-
nomic function by low HRV or low BRS is
also associated with nonfatal cardiovascu-
lar events and even with future risk of
hypertension (27–29); therefore, other
mechanisms must be involved. Auto-
nomic dysfunction could be a marker or
even a risk factor for endothelial dysfunc-
tion and atherosclerotic disease. The
present finding that impaired autonomic
function is especially harmful in subjects
at high risk may add strength to the
hypothesis that impaired autonomic
function may complicate underlying car-
diovascular disease rather than being a
risk factor. However, further studies are
needed to elucidate the involved mecha-
nisms.
The strength of the relation between
survival and autonomic function was de-
pendent on the presence of diabetes, hy-
pertension, or a history of cardiovascular
disease. This suggests that in subjects al-
ready at high risk, cardiovascular auto-
nomic dysfunction may be especially
hazardous.
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Figure 1—Kaplan-Meier curve stratified for
EI difference, based on the results of all subjects
for whom measurements were available (n 
554). The dotted line represents an EI differ-
ence107 ms, and the solid line represents an
EI difference107 ms, indicative of autonomic
dysfunction.
Table 3—Relative risks (95% CI) of autonomic dysfunction* for all-cause and cardiovascular mortality in subjects without (n 446) and with
diabetes (n 159) and in subjects at low risk (n 271) and high risk (diabetes and/or hypertension and/or cardiovascular disease) (n 334)
Parameter*
Without diabetes With diabetes
All cause Cardiovascular All cause Cardiovascular
Mean NN 1.43 (0.79–2.58) 1.21 (0.46–3.18) 1.69 (0.90–3.18) 1.29 (0.50–3.32)
SDNN 0.99 (0.54–1.84)† 1.33 (0.52–3.39) 1.72 (0.89–3.31)† 1.32 (0.51–3.42)
LF power 1.29 (0.70–2.36) 1.23 (0.46–3.31) 1.89 (0.98–3.65) 2.30 (0.82–6.43)
HF power 1.69 (0.94–3.02) 1.57 (0.61–4.02) 1.36 (0.72–2.59) 1.03 (0.40–2.67)
LF/(LF  HF) 0.67 (0.31–1.44) 1.29 (0.46–3.61) 1.73 (0.86–3.46) 1.90 (0.72–5.06)
EI difference 1.21 (0.66–2.21) 1.64 (0.64–4.17) 2.25 (1.13–4.45) 2.04 (0.74–5.65)
BRS 1.32 (0.72–2.41) 1.28 (0.47–3.53) 2.19 (1.11–4.34) 2.98 (1.08–8.25)
Low risk High risk
All cause Cardiovascular All cause Cardiovascular
Mean NN 1.14 (0.44–3.00) 0.96 (0.19–4.77) 1.66 (1.03–2.67) 1.46 (0.70–3.04)
SDNN 0.57 (0.19–1.73) 0.83 (0.16–4.22) 1.41 (0.88–2.28) 1.56 (0.75–3.24)
LF power 0.87 (0.31–2.47) 0.42 (0.05–3.55) 1.49 (0.92–2.42) 2.13 (1.01–4.49)
HF power 1.08 (0.40–2.90) 0.87 (0.17–4.52) 1.52 (0.94–2.45) 1.37 (0.66–2.85)
LF/(LF  HF) 0.20 (0.03–1.51) 0.50 (0.06–4.17) 1.33 (0.78–2.25) 2.09 (0.99–4.42)
EI difference 0.80 (0.29–2.24)† 0.82 (0.16–4.14)† 1.69 (1.02–2.80)† 1.75 (0.80–3.86)†
BRS 1.61 (0.63–4.10) 0.49 (0.06–4.14) 1.45 (0.88–2.40) 2.02 (0.93–4.39)
*The lowest 25th percentile values of the autonomic function parameters in the NGT group were considered the cutoff to define autonomic dysfunction: mean NN
878 ms; SDNN 25.7 ms; LF power 125 ms2. HF power 93 ms2; LF/(LFHF) 0.41; EI difference 107 ms; BRS 6.1 ms/mmHg. See Table 1 for definition of autonomic
function measures. Models in subjects without diabetes were adjusted for age, gender, and impaired glucose tolerance; models for subjects with diabetes were
adjusted for age, gender, and known diabetes; models for both low-risk and high-risk subjects were adjusted for age and gender. †Product-term (glucose tolerance
times autonomic function), P  0.05.
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